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Abstract  
Frontotemporal lobar degeneration with FUS-positive inclusions (FTLD-FUS) is a disease with 
unknown cause. Transportin1 (TRN1) is abundantly found in FUS-positive inclusions and responsible 
for the nuclear import of the FET proteins of which FUS is a member. The presence of all FET 
proteins in pathological inclusions suggests a disturbance of TRN1-mediated nuclear import. FUS also 
belongs to the heterogeneous nuclear ribonucleoprotein (hnRNP) protein family. We investigated 
whether hnRNP proteins are associated with FUS pathology implicating dysfunctional nuclear export 
in the pathogenesis of FTLD-FUS. hnRNP proteins were investigated in affected brain regions in 
FTLD-FUS using immunohistochemistry, biochemical analysis and the expression analysis. We 
demonstrated the presence of several hnRNP proteins in pathological inclusions including neuronal 
cytoplasmic inclusions and dystrophic neurites. Biochemical analysis revealed a shift in the location 
of hnRNP A1 from the nucleus to the cytoplasm. Expression analysis revealed an increase in several 
hnRNP proteins in FTLD-FUS. These results implicate a wider dysregulation of movement between 
intracellular compartments, than mechanisms only affecting the nuclear import of FUS proteins. 
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1. Introduction 
Recent advances in our understanding of the molecular mechanisms associated with 
frontotemporal lobar degeneration have shown that this heterogeneous group of diseases can be 
divided on the presence of the abnormal protein aggregates found in the pathological inclusions 
(Mackenzie et al., 2010). Fused in sarcoma (FUS) is a protein identified in pathological inclusions of 
patients clinically characterised with FTD and pathologically termed FTLD-FUS (Lashley et al., 2011; 
Munoz et al., 2009; Neumann et al., 2009) 
It is still unknown how FUS plays a role in the pathogenesis of FTLD-FUS and which of its many 
known functions are disrupted that leads to the formation of pathological lesions. FUS is a 
multifunctional protein composed of 526 amino acids belonging to the FET family of proteins, which 
also includes Ewings sarcoma protein (EWS) and TATA-binding protein associated factor 15 (TAF15) 
(Aman et al., 1996; Crozat et al., 1993; Kovar, 2011; Law et al., 2006; Yang et al., 2010). The FET 
family of proteins are all ubiquitously expressed nuclear proteins, which are highly conserved with 
predicted roles in RNA transcription, processing, transport and DNA repair (Bertrand et al., 1999; 
Crozat et al., 1993; Kovar, 2011; Law et al., 2006; Perrotti et al., 1998). They are also found to shuttle 
between the nucleus and the cytoplasm and their nuclear import is mediated by their non-classical 
nuclear localisation signal, called PY-NLS which is recognised by the nuclear import protein 
transportin-1 (TRN1). The pathological lesions in FTLD-FUS have been found to contain TRN1 
(Brelstaff et al., 2011), EWS and TAF15 in varying degrees (Davidson et al., 2013; Neumann et al., 
2012), suggesting that the pathogenic mechanism in FTLD-FUS is related to the dysfunction of 
transportin-mediated nuclear import affecting all FET proteins that are transported by TRN1 
(Neumann et al., 2012).  
FUS is structurally characterized by an N-terminal serine, tyrosine, glycine and glutamine-rich 
region, an RNA recognition motif (RRM), a C2/C2 zinc finger motif, multiple RGG repeat regions and 
a nuclear localisation signal (NLS) at the extreme C-terminus.  The C-terminal region of FUS contains 
multiple domains involved in RNA-protein interactions, while the N-terminus is involved in 
transcription activation (Prasad et al., 1994). Due to its distinct structure and function FUS also 
belongs to the heterogeneous nuclear ribonucleoproteins (hnRNPs) and is also known as hnRNP P2 
(Calvio et al., 1995).  
hnRNPs are a family of around twenty major polypeptides, hnRNPs A1 to U, which range in size 
from 34 to 120kDa (Pinol-Roma et al., 1988). Each protein contains at least one RNA-binding motif 
such as an RNA recognition motif (RRM), a hnRNP K homology domain or an arginine/glycine-rich 
(RGG) box (Dreyfuss et al., 1993; Krecic and Swanson, 1999). Some hnRNPs contain auxiliary domains 
with unusual amino acid compositions, which mediate protein-protein interactions (Cartegni et al., 
1996). Correlated with these diverse structural features a multitude of cellular functions have been 
ascribed to hnRNP proteins, including roles in DNA maintenance, recombination, transcription, 
processing of primary transcripts, mRNA nuclear export, subcellular localisation, translation and 
stability of mature mRNA (Busch and Hertel, 2012; Dreyfuss et al., 2002, 1993; Roy et al., 2014). 
hnRNPs A1 and A2 constitute 60% of the total protein mass of hnRNP particles, representing the 
most abundant nuclear proteins (Beyer et al., 1977). These proteins are associated with pre-mRNAs 
in the nucleus and appear to influence pre-mRNA processing and other aspects of mRNA metabolism 
and transport. While all hnRNPs are present in the nucleus, some shuttle between the nucleus and 
the cytoplasm and have distinct nucleic acid binding properties. FUS, along with other hnRNP 
proteins, is exported from the nucleus, probably bound to mRNA, and is immediately re-imported 
once dissociated. Its M9 domain acts as both a nuclear localization and nuclear export signal 
(Macara, 2001; Xu and Massagué, 2004). However, FUS can be distinguished from other hnRNPs 
notably by the presence of an N-terminal peptide sequence that can serve as a transcriptional 
activation domain (Zinszner et al., 1994).  
As FUS is a member of the hnRNP protein family we wished to investigate whether any other 
hnRNP proteins were associated with FUS pathology and if they could be implicated in the 
pathogenesis of FTLD-FUS. We studied the localization of proteins of the hnRNP family in affected 
brain regions in patients with FTLD-FUS and normal control brains by immunohistochemistry, 
biochemical analysis and investigated their expression using nanostring technology.  
  
2. Material and Methods 
2.1 Cases 
Brains were donated to the Queen Square Brain Bank for Neurological Disorders, UCL 
Institute of Neurology, University College London; the MRC London Brain Bank for 
Neurodegenerative Diseases, Institute of Psychiatry, King’s College, London, UK;  Neuropathology 
Department, Århus Kommunehospital, Århus, Denmark and NeuroResource, UCL Institute of 
Neurology, University College London. All cases had previously been diagnosed as NIFID (6 cases) or 
aFTLD-U (6 cases) characterised as having pathological inclusions that were immunoreactive for FUS 
and ubiquitin, but negative for both tau and TDP-43, with cases of the NIFID subgroup also 
containing α-internexin positive inclusions (Lashley et al., 2011). Ethical approval for the study was 
obtained from the National Hospital for Neurology and Neurosurgery Local Research Ethics 
Committee. 
2.2 Immunohistochemistry 
Seven-micron-thick tissue sections from the hippocampus, frontal cortex and spinal cord 
where cut from the following cases listed in table 1 (NIFID 1-6 and aFTLD-U 1-6) and 6 neurologically 
normal controls. Sections were deparaffinised in xylene and rehydrated using graded alcohols. 
Immunohistochemistry for all antibodies required pre-treatment with pressure cooker for 10 
minutes in citrate buffer pH6.0. Endogenous peroxidase activity was blocked (0.3% H202 in methanol, 
10 minutes) and non-specific binding with 10% dried milk solution. Tissue sections were incubated 
with the primary antibodies overnight at 40C, followed by biotinylated anti-rabbit IgG (1:200, 30 
minutes; DAKO) and ABC complex (30 minutes ; DAKO). Colour was developed with di-
aminobenzidine/H202 (Lashley et al., 2011). Table 2 lists all antibodies used in this study with supplier 
and concentrations used.  
2.3 Double-label Immunofluorescence  
This was applied to tissue sections of selected brain regions using an anti-FUS antibody in 
combination with the hnRNP A1 antibody that showed positive staining in the single stain 
preparations. After appropriate pre-treatment tissue sections were incubated with the secondary 
antibodies Alexa Fluor 488 and Alexa Fluor 568 (Molecular Probes, 1:300) for one hour at room 
temperature. 4’-6-diamidino-2-phenylindol (DAPI) was used for nuclear counterstaining. Sections 
were viewed with a Leica TCS4D confocal microscope using a 3-channel scan head and 
argon/krypton laser. 
 
 
 2.4 Biochemical fractionation and immunoblot analysis 
Two biochemical fractionation methods were employed to separate the cytosol from the 
nuclear fractions. Firstly a method for sequential extraction of proteins with increasing insolubility 
was adapted from Neumann et al, 2009. For this study we have analysed the frontal cortex grey 
matter from NIFID (cases 2,3 and 5) and an aFTLD-U case (case 5). Neurologically normal (n= 4) and 
Alzheimer’s disease cases (n=3) were also used as controls (Lashley et al., 2011; Neumann et al., 
2009).  
Protein concentration was determined by the BCA protein assay (Pierce, UK) and 10µg of 
high-salt buffer from each case were loaded onto 10% Bis-Tris gels (Invitrogen, UK) and run at 200V 
with MES (Invitrogen, UK) buffer under reducing conditions. Following electrophoresis, the proteins 
were transferred onto Hybond P membrane (GE Healthcare, UK) for 2hr at 40V. The membranes 
were blocked with 5% milk (Marvel) in PBS containing 0.1%Tween (PBS-T) and probed overnight with 
hnRNP A1 and β-actin antibodies. The membranes were washed in PBS-T three times for 5min each 
with shaking followed by incubating the blots with polyclonal HRP-conjugated secondary antibody 
(Santa Cruz, USA) at 1:2000 dilution for 30 min at room temperature. Following this, the membranes 
were washed thoroughly (three times for 5 min each with shaking). The specific bands were 
visualised by enhanced chemiluminesence (Pierce) and captured onto Biorad (Kodak, USA) 
membranes. The densities were quantified using Image J and the results expressed as a ratio.  
 
2.5 Nuclear and cytoplasmic fraction analysis 
One hundred mg of tissue was cut into small pieces and washed with 1XPBS containing 
protease inhibitors and centrifuged at 500g for 5min. Tissue was homogenised with a tissue grinder 
in  “cytoplasmic extraction reagent” (Thermo scientific) according to manufacturer’s instructions to 
separate nuclear and cytoplasmic fractions (NE-PER nuclear and cytoplasmic extraction reagents: 
Thermo Scientific).  Protein was measured using BCA protein assay (Pierce). 30µg and 10µg protein 
from the cytosolic and nuclear extracts were run for each sample respectively (NIFID cases, 2, 3 and 
5; aFTLD-U case 5; 3 AD cases) on 10% BIS-Tris gels (Invitrogen) and transferred onto hybond-P 
membrane (Amersham biosciences, VWR), blocked with 5% non-fat milk for 1hr at room 
temperature, incubated with mouse monoclonal primary antibody, hnRNPA1 (1:1000, Abcam) 
overnight at 4C. Protein loading was checked with beta actin antibody (monoclonal 1: 5000; Sigma) 
after stripping the blot with stripping solution (Thermo Scientific). For both antibodies HRP-
conjugated anti-mouse secondary (Santa Cruz) was used at 1:2000 dilution. Densitometric images 
after ECL detection were captured onto Kodak-X-OMat films (Sigma). Band intensity was quantitated 
using Image J Software and the graph and statistics were calculated using Graph-Pad Prism. One-way 
Anova was used to determine statistical significance between the sample groups.   
2.6 Nanostring nCounter assay and analysis 
Total RNA was extracted from the frontal and temporal cortices of 5 FTLD-FUS cases (NIFID cases 
1,2,3 and 5; aFTLD-U 4) and 6 neurologically normal controls using the RNeasy kit (Qiagen) as per the 
manufacturer’s instructions and RNA quality was evaluated using an Eppendorf 
Nanospectrophotometer. 100 ng of total RNA from each sample was analyzed with the NanoString 
nCounter analysis system (NanoString Technologies, Seattle, WA) using a pre-designed codeset. The 
codeset contained 17 probes for detection of the genes of interest (FUS, TAF15, EWS, TNPO1, hnRNP 
A1, hnRNP A2/B1, hnRNP C, hnRNP D, hnRNP F, hnRNP G, hnRNP H1, hnRNP H3, hnRNP L, hnRNP M, 
hnRNP R, hnRNP U). Probes were designed according to the manufacturer’s design principles (Geiss 
et al., 2008), including screening for inter- and intra-reporter and capture probe interactions, and 
selection for probes with optimal melting temperatures (Geiss et al., 2008). The laboratory running 
the assay was blinded to the diagnosis. To avoid run-order bias, samples of cases or controls were 
randomly assigned to plates. Raw counts were subjected to a technical normalization and 
normalized to the geometric mean using nSolver Analysis Software v2.0 (NanoString). Biological 
normalization using reference genes (CLTC, GAPDH, GUSB, HPRT1, PGK1, TUBB) included in the 
CodeSet was performed. Statistical analysis of Nanostring data was performed using Graphpad Prism 
5 software (GraphPad Software Inc.). 
3. Results 
Cases used for this study have been described clinically and pathologically in previous 
publications (Brelstaff et al., 2011; Lashley et al., 2011; Rohrer et al., 2011). The presence of EWS, 
TAF15 and the hnRNP proteins were investigated in the hippocampal and frontal cortical areas that 
have previously been shown to be affected by FUS pathology (Lashley et al., 2011). 
 
3.1  EWS and TAFF15 immunohistochemistry 
TAF15 showed staining of normal neuronal and glial nuclei in all cases and controls, although 
the intensity of the neuronal staining was dependent on formalin fixation time; the shorter the 
fixation time was the higher the intensity of the normal staining was. Both aFTLD-U and NIFID 
subtypes of FLTD-FUS showed strong TAF15 staining of neuronal cytoplasmic inclusions (figure 1, 
tables 3 and 4) and intranuclear inclusions previously seen with FUS antibodies. Antibodies against 
EWS showed nuclear staining of both neuronal and glial cells. It was noted that not all cases showed 
normal physiological nuclear staining of EWS and the numbers of inclusions stained varied between 
cases. However the two subtypes of FTLD-FUS investigated here showed EWS positive inclusions 
(figure 1, tables 3 and 4).  
3.2 hnRNP immunohistochemistry 
The presence of hnRNP proteins (A1, A2/B1, C, D, E, F, G, H, I, L M and U) in pathological 
inclusions was investigated in the hippocampal granular cell layer, CA1-CA4 hippocampal subregions, 
entorhinal cortex, frontal cortex and spinal cord and/or medulla wherever available. The presence of 
hnRNP proteins in pathological deposits were assessed as present (+) or absent (-) in the regions 
investigated (tables 3 and 4), as their frequency compared to FUS positive inclusions was low. All 
hnRNP proteins investigated were found in the both neuronal and glial nuclei in all FTLD-FUS cases 
regardless of their subtype (NIFID or aFTLD-U) and in neurologically normal controls. In cases 
previously diagnosed as NIFID hnRNP proteins A1, C, D, G, I and L were found in pathological 
inclusions (figure 2). hnRNP A1 was observed in neuronal cytoplasmic inclusions in the entorhinal 
cortex and frontal cortex in all 6 NIFID cases examined (figure 2a-b). hnRNP proteins C, D, G, I and L 
were observed in pathological inclusions in a number of NIFID cases (table 3, figure 2). It was noted 
that the majority of the hnRNP staining was observed in NIFID case 5 which lacked hippocampal FUS 
positive inclusions but contained sparse hippocampal hnRNP inclusions. hnRNP proteins A2/B1,E, F, 
H, M and U were not found in any pathological inclusions associated with disease in NIFID.   
Cases previously diagnosed as aFTLD-U showed the least amount of hnRNP staining (table 4) 
pathological inclusions only being positive for hnRNP A1, hnRNP D and hnRNP I. These positive 
inclusions were sparse compared to the number of inclusions found to be positive with FUS. No 
pathological inclusions were found to be positive with hnRNP A2/B1, C, E, F, G, H, L, M or U.  
 
3.3 FUS and hnRNP A1 double immunohistochemistry 
hnRNP A1 positive pathological inclusions were observed in the entorhinal and frontal cortex 
in all NIFID cases and two aFTLD-U cases (tables 3 and 4). Double label immunohistochemical 
analysis with anti-FUS showed that the hnRNP A1 and FUS co-localised in the same neuronal 
cytoplasmic inclusions and neuropil threads (figure 3). No hnRNP A1 positive inclusions were found 
in the granular cell layer of the dentate gyrus in any case. 
3.4 Cellular re-localisation of hnRNP A1 in FTLD-FUS 
In addition to observing hnRNP A1 in the FUS-positive pathological inclusions, we observed 
an increase in hnRNP A1 in the cytoplasm of neurons compared to that seen in normal controls in 
the frontal and temporal cortices (figure 3, arrows). This shift in protein localisation was not 
observed with other hnRNP proteins tested where the proteins were localised to the nucleus in both 
FTLD-FUS (data not shown) and normal controls. Nuclear and cytoplasmic biochemical fractionation 
was carried out to determine whether there were increased levels of hnRNP A1 in the cytoplasm of 
FTLD-FUS compared to normal controls.   
 A crude biochemical sequential fractionation was performed to separate the nuclear fraction 
from the cytoplasmic fraction (figure 4a). Probing the cytoplasmic fractions with an anti-hnRNP A1 
antibody showed a significant increase in cytoplasmic hnRNP A1 in FTLD-FUS compared to 
cytoplasmic expression of hnRNP A1 in both normal controls and Alzheimer’s disease cases (figure 
4b). This was repeated using a commercially available kit (Thermo scientific) to separate the cytosol 
from the nuclear fraction (figure 4c) which confirmed the previous observations in that there is an 
increase of hnRNP A1 protein expression in the cytoplasm of FTLD-FUS cases compared to normal 
controls and Alzheimer’s disease. 
3.5 Expression of hnRNP proteins in FTLD-FUS  
The expression of FUS, TAF15, EWS, TNPO1, hnRNP A1, hnRNP A2/B1, hnRNP C, hnRNP D, hnRNP 
F, hnRNP G, hnRNP H1, hnRNP H3, hnRNP L, hnRNP M, hnRNP R, hnRNP U were analysed using 
Nanostring technology for high-sensitive capture of mRNA transcripts (see supplementary table 1).  
The frontal and temporal cortices where analysed in FTLD-FUS (NIFID and aFTLD-U) and compared to 
frontal and temporal cortices from normal control cases with no pathological abnormalities. The 
normalised expression showed no significant difference in expression of FUS, TAF15, EWS, TNPO1, 
hnRNP A1, hnRNP C, hnRNP F, hnRNP G, hnRNP H1, hnRNP H3, hnRNP L, hnRNP M and hnRNP R, 
whereas a significant increase in expression of hnRNP A2/B1, hnRNP D, and hnRNP U was seen in 
FTLD-FUS cases (figure 5).  
4. Discussion 
In this study we have demonstrated that hnRNP proteins, associated with nuclear export, can be 
found in neuronal cytoplasmic inclusions and dystrophic neurites indicating an involvement of these 
proteins in the pathogenic mechanism of FTLD-FUS. The current suggested pathogenic mechanism of 
FTLD-FUS proposes that hypomethylation of the FET proteins, including FUS leads to an increased 
binding of TRN1 to these proteins causing a dysregulation of their TRN1-associated nuclear import 
(Dormann et al., 2012). We suggest that a broader dysfunction of not only nuclear import but also a 
disturbance of the nuclear export mechanism may be a contributing factor to disease pathogenesis. 
In our study we were able to detect hnRNP A1, D, G, I and L in pathological deposits in neurons, 
although only hnRNP A1 was shown through double label fluorescence immunohistochemistry to be 
co-localised with FUS in neuronal cytoplasmic inclusions and dystrophic neurites. hnRNP D, G, I and L 
were found in pathological deposits in the hippocampus of cases which were previously shown to 
lack FUS pathology (Lashley et al., 2011). It is of note that of the two different FTLD-FUS subtypes 
investigated here those originally diagnosed as NIFID showed hnRNP A1, D, G, I and L proteins in 
FUS-negative deposits whereas those diagnosed as aFTLD-U typically had hnRNP A1 positive 
deposits. Furthermore, in addition to hnRNP A1 co-localising with FUS-positive inclusions, our 
immunohistochemical studies also showed that in comparison with normal controls, hnRNP A1 
accumulated in a diffuse manner in the cytoplasm of neurons. This prompted us to perform 
biochemical analysis and we have shown a shift in cellular localisation of hnRNP A1 from the nucleus 
to the cytoplasm in FTLD-FUS compared to normal controls, suggesting that the normal function of 
this protein could be impaired due to its cellular re-localisation. mRNA expression analysis of FUS, 
TAF15, EWS and TRN1 showed no increase in expression between FTLD-FUS and normal controls, 
supporting the notion that a reduced expression of TRN1 does not play a role in the pathogenesis of 
FTLD-FUS. However, of the 11 hnRNP proteins investigated the expression of hnRNP A2/B1, hnRNP D 
and hnRNP U was significantly increased compared to normal controls, although hnRNP A2/B1 and 
hnRNP U were not present in the pathological inclusions, hnRNP D was found in the occasional FUS-
negative pathological deposit. The significance of the increased expression of hnRNP A2/B1, hnRNP 
D and hnRNP U requires further investigation. However, hnRNP A2/B1 overexpression plays a role in 
biogenesis and transport of mRNA in cancer (Yan-Sanders et al., 2002; Zhou et al., 1996). It is integral 
to cell proliferation and protein synthesis showing an increase in expression to cellular injury, and 
early indication of cell damage (Rajpurohit et al., 1994; Zhou et al., 1996). hnRNP D, also known as 
AU-rich element RNA-binding protein (AUF1), is an extensively studied AU-rich binding protein 
(AUBP). AUF1 has been shown to regulate mRNA turnover function to promote rapid mRNA 
degradation. AUF1 comprises a family of four related protein isoforms, with each isoform displaying 
multiple and distinct functions including the ability to target mRNA stability or decay, transcriptional 
activation of certain genes controlled by their different subcellular locations, expression levels, and 
post-translational modifications (Moore et al., 2014). Whilst hnRNP U has been shown to act as an 
accessory protein in DNA strand repair following oxidative damage (Dutta et al., 2015). 
FUS belongs to the FET family of proteins and we have confirmed previous findings showing 
that the other members, TAF15 and EWS, are present in the FUS-positive inclusions found in FTLD-
FUS (Neumann et al., 2011). Protein interaction studies have revealed that FET proteins are able to 
interact with each other forming protein complexes, therefore any disruption of the nuclear import 
of FUS would also result in accumulation of TAF15 or EWS in the inclusions (Kovar, 2011; Pahlich et 
al., 2008). Due to its distinct structure and function FUS also belongs to the hnRNP family and is also 
known as hnRNP P2 (Calvio et al., 1995). FUS, along with other hnRNP proteins, is exported from the 
nucleus by binding to mRNA, and, once dissociated from it FUS is immediately re-imported into the 
nucleus via the TRN1 mediated process (Brelstaff et al., 2011; Dormann et al., 2010). According to a 
current hypothesis hypomethylated FET proteins have an increased binding affinity for TRN1 
resulting in the build-up of such FET-TRN1 complexes in the cytoplasm overtime (Dormann et al., 
2012). The presence of both FUS and TRN1 in neuronal intranuclear inclusions, as confirmed by our 
previous study, indicates that such abnormal FET-TRN1 complexes are able to shuttle into the 
nucleus (Brelstaff et al., 2011). The presence of normal nuclear FUS staining in a proportion of 
neurons with cytoplasmic and/or intranuclear inclusions indicates that FET proteins are able to 
dissociate from TRN1, consistent with the finding that hypomethylation of the FET protein only 
slightly increases their binding affinity to TRN1 (Dormann et al., 2010; Lashley et al., 2011; Neumann 
et al., 2012). One can hypothesise that due to the increased binding of FUS (and the other FET 
proteins) to TRN1 in the cytoplasm and nucleus will also compromise the nuclear export of FUS. This 
may also result in a disruption of the nuclear export of other hnRNP proteins, as under normal 
conditions shuttling hnRNPs are able to bind to each other through their auxiliary domains forming 
protein complexes. We found that hnRNP A1 was present in FUS-positive neuronal cytoplasmic 
inclusions in both NIFID and aFTLD-U. A previous study failed to show the presence of hnRNP A1 in 
pathological inclusions in two subtypes of BIBD and aFTLD-U; however it did not investigate this in 
NIFID (Neumann et al., 2012).  
Dense cytoplasmic staining was also evident with hnRNP A1 immunohistochemistry and, 
although an increase in expression of hnRNP A1 mRNA was not evident, biochemical analysis 
showed an increase in cytoplasmic hnRNP A1 in FTLD-FUS suggesting a disruption of its normal 
functions. Although the focus of the current study was to investigate the hnRNP proteins involved in 
nuclear export, the presence of hnRNP A1 in the pathological inclusions adds evidence that defective 
TRN1-mediated nuclear import is not restricted to FET proteins as hnRNP A1 is also a cargo protein 
of TRN1 (Lee et al., 2006). Therefore investigating whether TRN1 mediated nuclear import of hnRNP 
A1 is regulated by arginine methylation in a similar fashion to the FET proteins remains to be shown. 
Previous studies have shown that there are subtle differences in the staining patterns of the 
FET proteins with EWS being present in a proportion of FUS-positive inclusions in aFTLD-U cases, 
whereas in NIFID and BIBD the EWS staining is more consistent and inclusions are more robustly 
labelled (Davidson et al., 2013; Neumann et al., 2011). This was mirrored with our hnRNP 
immunohistochemistry with NIFID showing more hnRNP proteins in inclusions than aFTLD-U. It was 
also noted that TRN1, TAF15 and EWS were always found in pathological FUS-immunoreactive 
inclusions. However, hnRNP D, G, I and L were found in regions and deposits where no FUS 
pathology was seen. It is of note that for the present study tissue was only available from previously 
diagnosed subtypes NIFID and aFTLD-U. Cases previously diagnosed as BIBD are a rarer subtype of 
FTLD-FUS and weren’t available for this study. 
Disruption of nuclear import mechanisms can result in the redistribution of proteins from 
the nucleus to the cytoplasm, which has been strongly implicated in the pathogenesis of FUS 
proteinopathies (Lagier-Tourenne et al., 2010; Wang et al., 2008). The hypothesis that cytoplasmic 
redistribution of FUS is central to the pathogenesis of FTLD-FUS is supported by several studies 
showing that FUS is recruited into stress granules due to cellular stress disrupting nuclear transport 
ALS-FUS and FTLD-FUS (Dormann et al., 2010) and cell culture experiments demonstrating that 
modification to the nuclear localisation signal of FUS disrupts the binding to TRN1 resulting in failure 
of the nuclear import of FUS in familial ALS-FUS (Dormann et al., 2010). However, this is a time 
dependent mechanism as the FUS protein accumulates in neuronal cytoplasmic and intranuclear 
inclusions but also normal nuclear staining of FUS remains suggesting that FUS continues to be 
imported into the nucleus (Lashley et al., 2011).  
In summary this study has demonstrated the co-accumulation of hnRNP A1 in a proportion 
of FUS-positive inclusions in the NIFID and to a lesser extent in aFTLD-U subtypes of FTLD-FUS. The 
accumulation of hnRNP D, I, G and L involved in nuclear export are found in pathological deposits 
negative for FUS and may play a role in the pathological process. Subtle differences in the 
pathogenic pathways maybe involved in the different FTLD-FUS subtypes as more hnRNP proteins 
were found deposited in the NIFID subtype. Hypomethylation of the FET proteins increasing the 
binding affinity to TRN1 has been suggested as a possible mechanism involved in FTLD-FUS. Through 
the increased binding affinity of FUS to TRN1, whether the FUS-TRN1 complex is sequestered in 
neuronal cytoplasmic or nuclear inclusions, the involvement of FUS in the nuclear export 
mechanisms will be impaired. Therefore we suggested that a disruption of the nuclear export 
pathways should also be considered as potential mechanisms in FTLD-FUS.  
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FIGURE LEGENDS 
Table 1: Demographic data of cases with FUS-positive inclusions. *aFTLD-U2 (son) is related to 
aFTLD-U6 (mother) 
 
Table 2: Antibodies used in this study. 
Table 3: Summary of hnRNP immunohistochemical staining in neuronal intermediate filament 
inclusion disease (NIFID). Qualitative analysis of the presence of hnRNP proteins in pathological 
deposits. ‘+’ shows the depicted protein was found in a pathological deposits; ‘-‘ the depicted 
protein was absent from pathological deposits. NCI – neuronal cytoplasmic inclusions; NT – neuropil 
threads. 
 
Table 4: Summary of hnRNP immunohistochemical staining in atypical frontotemporal lobar 
degeneration (aFTLD-U). Qualitative analysis of the presence of hnRNP proteins in pathological 
deposits. ‘+’ shows the depicted protein was found in a pathological deposits; ‘-‘ the depicted 
protein was absent from pathological deposits. NCI – neuronal cytoplasmic inclusions; NT – neuropil 
threads. 
 
Figure 1: FET pathology in FTLD-FUS. FET proteins are present in the pathological inclusions of NIFID 
(a, c,e,g,I, and k) and aFTLD-U (b,d,f,h,j, and l). FUS is present in neuronal cytoplasmic inclusions in 
the frontal cortex of NIFID (a) and motor neurons in the spinal cord (c), which was also seen in 
aFTLD-U cases (b and d). A similar staining pattern was seen with TAF15 (e-h) and EWS (i-l). Bar on a 
represents 40μm on a-b, e-f, i-j and 5μm on c-d, g-h, k-l. 
 
Figure 2: hnRNP immunohistchemistry in NIFID (NIFID 4). Several hnRNP proteins were found in 
pathological deposits in FTLD-FUS. hnRNP A1 was observed in neuronal cytoplasmic inclusions in the 
frontal cortex (a and b). hnRNP D was found in neuronal cytoplasmic inclusions and in dystrophic 
neurites in the subiculum (c-f). hnRNP G was the only hnRNP protein to be found in the granular cells 
of the dentate fascia and dystrophic neurites (g and h). hnRNP I was found deposited in neuronal 
cytoplasmic deposits and dystrophic neurites (i-k). Bar in A represents 10μm in a, b, g and k; 20μm in 
h-j and f; 40μm in c-e.  
Figure 3: Double immunohistochemistry and dense cytoplasmic hnRNP A1 staining (NIFID 4). 
Double immunohistochemistry with FUS and hnRNP A1 highlights the co-localisation of both 
proteins in neuronal cytoplasmic inclusions (double white arrows) and dystrophic neurites (single 
white arrows). hnRNP A1 immunohistochemistry in FTLD-FUS shows an increase in cytoplasmic 
hnRNP A1 compared to normal controls (arrows). 
 
Figure 4: Figure 4: Biochemical fractionation of cytoplasmic extracts showing an increase of 
hnRNPA1 in the cytoplasmic fractions of FTLD-FUS cases compared to normal controls and AD 
cases. Biochemical fractionation was carried out using a sequential extraction from the frontal 
cortices from FTLD-FUS (NIFID 2 and 3; aFTLD-U 3 and 5), four pathologically normal controls and 
three AD cases (a). The amount of hnRNP A1 in the cytoplasmic extract was compared to the 
amount of β-actin found in each sample (b), a significant increase in hnRNP A1 was seen in the FTLD-
FUS compared with normal controls and AD cases. Nuclear and cytoplasmic fractions were prepared 
using a commercially available separation kit (Thermo Scientific), confirming the increase of hnRNP 
A1 in the cytosolic fraction but with the retention of the hnRNP A1 in the nuclear fraction (c).   
 
Figure 5: Nanostring expression analysis of hnRNP mRNA levels in FTLD-FUS. The expression of the 
FET, Transportin (TNP1) and the hnRNP mRNA levels were investigated in the frontal and temporal 
cortices of FTLD-FUS compared to normal controls. A significant increase in expression was identified 
for hnRNP A2/B1, hnRNP D and hnRNP U. No significant differences were found for other hnRNP 
mRNA’s investigated.  
 
Supplementary tables: 
Supplementary table 1: Gene information table for nanostring analysis.  
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